Targeted, immediate antibiotics following a positive dipstick test may be the optimal management strategy

Kurt G Naber


This interesting, prospective, and randomised clinical study tested five different approaches in the treatment of women suspected with uncomplicated urinary-tract infection (UTI): immediate, empirical, antibiotic therapy (AT); delayed (by 48 h), empirical AT; empirical AT offered to patients showing a certain clinical symptom score; empirical AT offered to patients with positive dipstick urinalysis; and targeted AT offered according to the results of a midstream urine microbiological culture and symptomatic treatment up to the point when the microbiological results became available.

The study included 309 non-pregnant women aged between 18 and 70 years. All groups were comparable in terms of demographics, clinical characteristics and frequency of symptom severity at the time of study. The study aimed to achieve a similar-level reduction of symptoms without unnecessary antibiotic usage, laboratory investigations and reconsultations. A statistical consideration of sample size was performed for α=0.05 and β=0.2 for multiple groups. Patients with clinical symptoms who did not require immediate AT were included.

The patients had access to antibiotics at their request, despite randomisation. The use of midstream urine culture and dipsticks when not indicated on the advice sheets was also assessed. The study managed to represent the clinical ambulatory situation in a general practice.

According to the analysis, the authors concluded that all five management strategies achieved similar (but not equivalent) symptom reduction; there was no advantage in routinely sending midstream urine samples for microbiological testing, and antibiotics targeted with dipsticks with a delayed prescription as backup, or empirical delayed prescription, can help to reduce antibiotic use.

Are these conclusions justified by the data presented?

The Methods stated that group 1 was offered ‘immediate’ empirical AT. However, in the Results section it is stated that, on an average, antibiotics were started after 1.19 days in group 1, 1.40 days in group 3 (symptom score) and 1.48 days in group 4 (dipstick urinalysis). Therefore, in none of the three groups was AT commenced immediately and was usually delayed by, at least, 1 day.

The study showed that women who were delayed antibiotic treatment for 48 h or more were likely to have a 37% longer duration of symptoms rated as moderately bad (p<0.001). This (statistically significant) difference may be considered clinically relevant. However, if AT in groups 1, 3 and 4 had commenced immediately on the day of consultation, and not the next day as the data in the results suggest, it seems likely that this difference should be increased by another day.

Interestingly, in group 1, 97% used antibiotics, whereas in groups 3 (symptom score) and 4 (dipstick urinalysis) only 90% and 80% did so, even though symptom control was similar between groups, and would have been most likely also similar if AT was commenced on the day of consultation. Therefore, preselection of patients with a positive dipstick (if nitrite or leucocytes and a trace of blood is detected in urine) for immediate AT will reduce antibiotic usage without compromise in symptom control. Only patients with a negative dipstick urinalysis should be offered delayed empiric AT, for it is also known that UTI may be present in patients with negative dipstick and these patients may profit more from AT than from placebo.1

A previous validation study had shown that dipsticks and clinical scoring algorithms can potentially help improve predictive values of UTI.2 The present study confirms the usefulness of this strategy by measuring clinical outcome and antibiotic usage. A shortcoming specific to this study was that a group of patients preselected with dipstick and clinical scoring were not investigated, which may have further reduced the number of patients who were offered immediate AT.

I would like to suggest slightly modified conclusions and recommendations, taking into consideration the cited studies:

1. Early empiric AT as compared with delayed AT of more than 48 h can help control symptoms faster. Therefore, if AT is indicated, it should be started immediately on the day of consultation. There is no advantage in routinely sending midstream urine samples for microbiological investigations and delay AT while waiting for the results.

2. Immediate empiric AT should be offered only to patients with positive dipstick urinalysis and clinical scoring, in order to minimise unnecessary antibiotic usage.

3. Because patients with positive dipstick urinalysis may profit from AT, delayed AT should be offered to those patients if symptoms persist after 48 h.

This strategy may be the best possible compromise between fast symptom control and reduction of unnecessary antibiotic use.

Competing interests KGN has been paid as an investigator by MerLion, OM Pharma, Peninsula/Johnson & Johnson, Sanofi-Aventis and Zambon. He also has been paid as speaker at scientific meetings/scientific publications by

do: 10.1136/ebm1068

Technical University of Munich, Munich, Germany

Correspondence to:
Kurt G Naber
Karl-Bickleder-Str. 44c, 94315 Straubing, Germany; kurt@nabers.de

Evidence-Based Medicine June 2010 | volume 15 | number 3 |
Bayer, DaiichiSankyo, Johnson & Johnson, OM-Pharma, Sanofi-Aventis and Zambon.

References
Targeted, immediate antibiotics following a positive dipstick test may be the optimal management strategy

Kurt G Naber

*Evid Based Med* 2010 15: 90-91
doi: 10.1136/ebm1068

Updated information and services can be found at:
http://ebm.bmj.com/content/15/3/90

These include:

**References**
This article cites 3 articles, 3 of which you can access for free at:
http://ebm.bmj.com/content/15/3/90#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Editor's choice (92)
- Urinary tract infections (35)
- Urinary tract infections (35)
- Vulvovaginal disorders (75)
- Chemotherapy (82)
- Clinical trials (epidemiology) (1595)
- Immunology (including allergy) (571)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/